Margarita Papatheodoridi1, Jean Baptiste Hiriart2, Monica Lupsor-Platon3, Fabrizio Bronte4, Jerome Boursier5, Omar Elshaarawy6, Fabio Marra7, Maja Thiele8, Georgios Markakis9, Audrey Payance10, Edgar Brodkin1, Laurent Castera10, George Papatheodoridis9, Aleksander Krag8, Umberto Arena7, Sebastian Mueller6, Paul Cales5, Vincenza Calvaruso4, Victor de Ledinghen2, Massimo Pinzani1, Emmanuel A Tsochatzis11. 1. UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, UK. 2. INSERM U1053, Bordeaux University, Bordeaux, France. 3. Department of Medical Imaging, Regional Institute of Gastroenterology and Hepatology, Prof. Dr. Octavian Fodor", University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj-Napoca, Romania. 4. Gastroenterology and Hepatology Unit, Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialities, PROMISE. University of Palermo, Italy. 5. Liver-Gastroenterology Department, University Hospital, Angers, France. 6. Center for Alcohol Research, University of Heidelberg, Heidelberg, Germany. 7. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. 8. Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark. 9. Academic Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece. 10. Service d'Hépatologie, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France. 11. UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, UK. Electronic address: e.tsochatzis@ucl.ac.uk.
Abstract
BACKGROUND: The Baveno VI consensus proposed a dual liver stiffness (LS) by transient elastography threshold of <10 and >15 kPa for excluding and diagnosing compensated advanced chronic liver disease (cACLD) in the absence of other clinical signs. Herein, we aimed to validate these criteria in a real-world multicentre study. METHODS: We included 5,648 patients (mean age 51 ± 13 years, 53% males) from 10 European liver centres who had a liver biopsy and LS measurement within 6 months. We included patients with chronic hepatitis C (n = 2,913, 52%), non-alcoholic fatty liver disease (NAFLD, n = 1,073, 19%), alcohol-related liver disease (ALD, n = 946, 17%) or chronic hepatitis B (n = 716, 13%). cACLD was defined as fibrosis stage ≥F3. RESULTS: Overall, 3,606 (66%) and 987 (18%) patients had LS <10 and >15 kPa, respectively, while cACLD was histologically confirmed in 1,772 (31%) patients. The cut-offs of <10 and >15 kPa showed 75% sensitivity and 96% specificity to exclude and diagnose cACLD, respectively. Examining the ROC curve, a more optimal dual cut-off at <7 and >12 kPa, with 91% sensitivity and 92% specificity for excluding and diagnosing cACLD (AUC 0.87; 95% CI 0.86-0.88; p <0.001) was derived. Specifically, for ALD and NAFLD, a low cut-off of 8 kPa can be used (sensitivity=93%). For the unclassified patients, we derived a risk model based on common patient characteristics with better discrimination than LS alone (AUC 0.74 vs. 0.69; p <0.001). CONCLUSIONS: Instead of the Baveno VI proposed <10 and >15 kPa dual cut-offs, we found that the <8 kPa (or <7 kPa for viral hepatitis) and >12 kPa dual cut-offs have better diagnostic accuracy in cACLD. LAY SUMMARY: The term compensated advanced chronic liver disease (cACLD) was introduced in 2015 to describe the spectrum of advanced fibrosis and cirrhosis in asymptomatic patients. It was also suggested that cACLD could be diagnosed or ruled out based on specific liver stiffness values, which can be non-invasively measured by transient elastography. Herein, we assessed the suggested cut-off values and identified alternative values that offered better overall accuracy for diagnosing or ruling out cACLD.
BACKGROUND: The Baveno VI consensus proposed a dual liver stiffness (LS) by transient elastography threshold of <10 and >15 kPa for excluding and diagnosing compensated advanced chronic liver disease (cACLD) in the absence of other clinical signs. Herein, we aimed to validate these criteria in a real-world multicentre study. METHODS: We included 5,648 patients (mean age 51 ± 13 years, 53% males) from 10 European liver centres who had a liver biopsy and LS measurement within 6 months. We included patients with chronic hepatitis C (n = 2,913, 52%), non-alcoholic fatty liver disease (NAFLD, n = 1,073, 19%), alcohol-related liver disease (ALD, n = 946, 17%) or chronic hepatitis B (n = 716, 13%). cACLD was defined as fibrosis stage ≥F3. RESULTS: Overall, 3,606 (66%) and 987 (18%) patients had LS <10 and >15 kPa, respectively, while cACLD was histologically confirmed in 1,772 (31%) patients. The cut-offs of <10 and >15 kPa showed 75% sensitivity and 96% specificity to exclude and diagnose cACLD, respectively. Examining the ROC curve, a more optimal dual cut-off at <7 and >12 kPa, with 91% sensitivity and 92% specificity for excluding and diagnosing cACLD (AUC 0.87; 95% CI 0.86-0.88; p <0.001) was derived. Specifically, for ALD and NAFLD, a low cut-off of 8 kPa can be used (sensitivity=93%). For the unclassified patients, we derived a risk model based on common patient characteristics with better discrimination than LS alone (AUC 0.74 vs. 0.69; p <0.001). CONCLUSIONS: Instead of the Baveno VI proposed <10 and >15 kPa dual cut-offs, we found that the <8 kPa (or <7 kPa for viral hepatitis) and >12 kPa dual cut-offs have better diagnostic accuracy in cACLD. LAY SUMMARY: The term compensated advanced chronic liver disease (cACLD) was introduced in 2015 to describe the spectrum of advanced fibrosis and cirrhosis in asymptomatic patients. It was also suggested that cACLD could be diagnosed or ruled out based on specific liver stiffness values, which can be non-invasively measured by transient elastography. Herein, we assessed the suggested cut-off values and identified alternative values that offered better overall accuracy for diagnosing or ruling out cACLD.
Authors: Thierry Thévenot; Sophie Vendeville; Delphine Weil; Linda Akkouche; Paul Calame; Clémence M Canivet; Claire Vanlemmens; Carine Richou; Jean-Paul Cervoni; Marie-France Seronde; Vincent Di Martino; Jérôme Boursier Journal: PLoS One Date: 2022-05-26 Impact factor: 3.752
Authors: Fasiha Kanwal; Jay H Shubrook; Leon A Adams; Kim Pfotenhauer; Vincent Wai-Sun Wong; Eugene Wright; Manal F Abdelmalek; Stephen A Harrison; Rohit Loomba; Christos S Mantzoros; Elisabetta Bugianesi; Robert H Eckel; Lee M Kaplan; Hashem B El-Serag; Kenneth Cusi Journal: Gastroenterology Date: 2021-09-20 Impact factor: 33.883
Authors: Victoria Blanes-Vidal; Katrine P Lindvig; Maja Thiele; Esmaeil S Nadimi; Aleksander Krag Journal: Sci Rep Date: 2022-02-21 Impact factor: 4.379
Authors: Ferenc Emil Mózes; Jenny A Lee; Emmanuel Anandraj Selvaraj; Arjun Narayan Ajmer Jayaswal; Michael Trauner; Jerome Boursier; Céline Fournier; Katharina Staufer; Rudolf E Stauber; Elisabetta Bugianesi; Ramy Younes; Silvia Gaia; Monica Lupșor-Platon; Salvatore Petta; Toshihide Shima; Takeshi Okanoue; Sanjiv Mahadeva; Wah-Kheong Chan; Peter J Eddowes; Gideon M Hirschfield; Philip Noel Newsome; Vincent Wai-Sun Wong; Victor de Ledinghen; Jiangao Fan; Feng Shen; Jeremy F Cobbold; Yoshio Sumida; Akira Okajima; Jörn M Schattenberg; Christian Labenz; Won Kim; Myoung Seok Lee; Johannes Wiegand; Thomas Karlas; Yusuf Yılmaz; Guruprasad Padur Aithal; Naaventhan Palaniyappan; Christophe Cassinotto; Sandeep Aggarwal; Harshit Garg; Geraldine J Ooi; Atsushi Nakajima; Masato Yoneda; Marianne Ziol; Nathalie Barget; Andreas Geier; Theresa Tuthill; M Julia Brosnan; Quentin Mark Anstee; Stefan Neubauer; Stephen A Harrison; Patrick M Bossuyt; Michael Pavlides Journal: Gut Date: 2021-05-17 Impact factor: 23.059